OpenAI acquires startup Orchestra Bio to beef up its biotech business
Startup's team and technology will support OpenAI's Rosalind life sciences initiative
OpenAI has agreed to acquire biotechnology start-up Orchestra Bio to expand its capabilities in life-sciences research. Personnel and assets from the company will be integrated into Rosalind, OpenAI's model for biological applications, as well as its related Workbench platform. The tooling is designed to assist scientists with experimental workflow planning and data analysis.
Original source
This summary was written by the GPU Data Hub desk from reporting published by TechCrunch on 20 Oct 2026, 20:35. Read the full article at the original publisher.
Read Original Source →